Enliven Therapeutics

ELVN
46.5300.26% ( +0.120 )
Closed: Nov 20, 16:00:00 (EDT)

Valuation

Current ValuationThe current P/E ratio is -30.18, below the reasonable range, cheaper than 90.64% of the time in the past 5 years, and the industry ranks 210/255, the industry Median -0.87.

-30.18xP/E
Stock price$46.53Earnings per share$-1.54

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
03468102136

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BAYRYUSBayer
-35.48x--$58.98B
BAYZFUSBayer Aktiengesellschaft
-36.05x--$59.93B
VTRSUSViatris
-37.03x91.33%$22.50B
ELANUSElanco Animal Health
-87.52x164.80%$12.87B
AXSMUSAxsome Therap
-43.26x30.77%$6.80B
ABVXUSAbivax SA
-13.72x22.99%$6.38B
CURLFUSCuraleaf Holdings, Inc.
-257.01x--$5.30B
BLTEUSBelite Bio
-46.24x25.00%$5.13B
MANEUSVeraDermics
-48.61x97.55%$4.99B
VREOFUSVIREO GROWTH INC
-76.65x--$4.97B
LQDAUSLiquidia Tech
-52.07x91.61%$4.90B
DFTXUSDefinium Therapeutics
-11.50x43.16%$3.88B
TARSUSTarsus Pharmaceuticals
-5.13x879.07%$3.60B
ELVNUSEnliven Therapeutics
-30.18x5.91%$3.42B
AMLXUSAmylyx Pharmaceuticals
-20.50x0.72%$3.35B
XERSUSXeris Biopharma
-477.28x--$3.10B
BHCUSBausch Health
-3.66x511.90%$3.08B
MBXUSMBX Biosciences
-16.45x49.14%$2.39B
PRGOUSPerrigo
-1.25x65.45%$2.21B
PHVSUSPharvaris BV
-10.55x15.00%$2.20B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.